Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline [Yahoo! Finance]
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: Yahoo! Finance
Proceeds to support advancing AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor SAN DIEGO, March 26, 2024 BUSINESS WIRE Avenzo Therapeutics, Inc . ("Avenzo"), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing. The total capital raised since the company's founding in August 2022 is $347 million. The financing round includes nine new investors and was led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital, with participation from additional new investors, including INCE Capital, TF Capital, Delos Capital, and Quan Capital. In conjunction with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors. Proceeds from the financing will be used to advance Avenzo's emerging oncology pipeline which is led
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target lowered by analysts at Stifel Nicolaus from $4.80 to $2.30. They now have a "hold" rating on the stock.MarketBeat
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressBusiness Wire
ATRA
Earnings
- 3/28/24 - Beat
ATRA
Analyst Actions
- 4/1/24 - Stifel
ATRA
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 4/12/24 - Form PRE
- ATRA's page on the SEC website